Fig. 5From: Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world studyUnivariate analysis of OS in patients with MT. Age, sex, smoking history, pathological type, distant metastasis, clinical stage, and medical insurance were analyzed. Patients with adenocarcinoma and without distant metastasis gained more OS benefit from MT (P = 0.041 and P = 0.037, respectively; log-rank tests). MT, maintenance therapy; OS, overall survivalBack to article page